Compare FNF & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNF | BMRN |
|---|---|---|
| Founded | 1847 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 11.4B |
| IPO Year | 2005 | 1999 |
| Metric | FNF | BMRN |
|---|---|---|
| Price | $50.44 | $59.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 18 |
| Target Price | $60.50 | ★ $88.22 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | 0.54 |
| Revenue | ★ $14,445,000,000.00 | $1,313,646,000.00 |
| Revenue This Year | $10.90 | $15.02 |
| Revenue Next Year | $5.44 | $12.23 |
| P/E Ratio | ★ $56.75 | $110.20 |
| Revenue Growth | 5.58 | ★ 17.62 |
| 52 Week Low | $42.78 | $49.26 |
| 52 Week High | $61.40 | $66.28 |
| Indicator | FNF | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 59.39 | 56.96 |
| Support Level | $45.20 | $54.24 |
| Resistance Level | $57.63 | $60.22 |
| Average True Range (ATR) | 1.16 | 1.41 |
| MACD | 0.25 | -0.10 |
| Stochastic Oscillator | 57.11 | 59.94 |
Fidelity National Financial Inc is a provider of (i) title insurance, escrow and other title-related services, including trust activities, trustee sales guarantees, recordings and reconveyances and home warranty and (ii) transaction services to the real estate and mortgage industries. It operates in three segments: Title, F&G, Corporate and Other. The title segment that derives the majority of revenue consists of the operations of title insurance underwriters and related businesses, which provide title insurance and escrow and other title-related services including trust activities, trustee sales guarantees, and home warranty products. All of the company's revenue is generated in the United States.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.